Ok, I finished dinner and have a second.
I'm skimming this paper now, but I want to look at some things. For example, if we take the largest sample size studies we find (not including prophylactic)
Lopez-Medina, double-blind placebo, n= 476.
No finding to support the use of ivermectin for mild COVID19.
Mahmud, double-blind, placebo + SOC, n = 363.
This had a positive finding, reduction of symptoms by 2 days. But this also included both ivermectin and doxycycline vs placebo and SOC.
Elgazzar, n = 200 - withdrawn for fraud
Niaee - dosing study, 180 patients in six arms,
positive result for hospitalized / severe covid, but as the authors note very effective small sample size due to the way the study was structured
Fonseca - kind of a strange study, mainly focused on HCQ and prednisone, but also included ivermectin. Positive result for HCQ (go figure) but
negative result for ivermectin. Lots of heterogeneity, as the authors note.
Mohan - double-blind placebo, two dosing arms, n = 152.
No statistically significant result, but the absolute values favor ivermectin.
Hashim - quasi-RCT, n = 140,
positive finding, reduced time to recovery All other results not statistically significant (P>.05)
Chowhury - quasi-RCT, n= 116.
No statistically significant result, but the trend favors ivermectin.
ok im tired of this. i want to see their study redone with Elgazzar taken out, but from the larger studies here I think all we can conclude is that maybe doxycycline helps reduce symptoms.
haha sorry I just came across this
https://www.nature.com/articles/d41586-021-02081-wQuote:
Before its withdrawal, the paper was viewed more than 150,000 times, cited more than 30 times and included in a number of meta-analyses that collect trial findings into a single, statistically weighted result. In one recent meta-analysis in the American Journal of Therapeutics that found ivermectin greatly reduced COVID-19 deaths, the Elgazzar paper accounted for 15.5% of the effect.
One of the authors of the meta-analysis, statistician Andrew Bryant at Newcastle University, UK, says that his team corresponded with Elgazzar before publishing the work to clarify some data. "We had no reason to doubt the integrity of [Professor] Elgazzar," he said in an e-mail. He added that in a pandemic setting, no one can reanalyse all of the raw data from patient records when writing a review. Bryant went on to say that his group will revise the conclusion if investigations find the study to be unreliable. However, even if the study is removed, the meta-analysis would still show that ivermectin causes a major reduction in deaths from COVID-19, he says.
Bryant's paper is the one in question.